Recent Updates in Molecular Targets and Pathways in Lung Cancer

Edward S. Kim, MD, MBA, discusses the importance of trastuzumab deruxtecan in HER2-mutated non–small cell lung cancer.

George Simon, MD, FACP, FCCP, discusses the evaluation of datopotamab deruxtecan in TROP-2–overexpressing solid tumors.

Julie R. Brahmer, MD, MSc, discusses the examination of nemvaleukin alfa in solid tumors.

HER3 has been shown to have a small amount of tyrosine kinase activity, making it an attractive target for the treatment of patients who have progressed after treatment with tyrosine kinase inhibitors. Preclinical data have shown that targeting HER3 and EGFR can overcome acquired resistance to EGFR inhibition.

Paul Bunn, MD, elaborates on carcinoembryonic antigen–related cell adhesion molecule 5 as a potential target in the treatment of non–small cell lung cancer.

Clinicians looking for additional options for the treatment of patients with non–small cell lung cancer may soon be gaining another actionable biomarker with the emergence of exciting new data concerning targeting the cell-surface glycoprotein TROP-2.

Targeted treatment options for patients with HER2-mutant non–small cell lung cancer have been slow to reach benchmarks for approval given the limited patient populations harboring this disease characteristic.

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the use of antibody-drug conjugates (ADCs) in HER2-mutated non–small cell lung cancer.

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the evaluation of CEACAM5 biomarker testing in non–small cell lung cancer.

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss second-line treatment options for patients with non—small cell lung cancer who progressed on first-line EGFR-directed tyrosine kinase inhibitors.